May 18, 2026
Pharma has invested heavily in bringing therapy closer to patients. But from the vantage point of the pharmacy counter, something critical is missing. Pleio’s Chief Pharmacy Officer Mark Gregory writes for MM&M on the emotional barriers DTP programs consistently overlook, and what it takes to build patient support that actually works. Mark makes the case that as DTP models expand and the medication journey becomes increasingly decentralized, pharmacist insight into how patients experience and discontinue therapy should shape program design from the start.
April 27, 2026
In an interview with Pharmacy Times at Asembia’s AXS26 Summit, Michael Oleksiw, CEO of Pleio addressed the challenge of medication nonadherence in specialty therapy, where nearly half of all treatment failures are tied to adherence issues. Mechanical interventions like push notifications alone fall short; overcoming nonadherence in specialty therapies requires AI-driven insights paired with human-centered outreach to tackle the emotional and psychological barriers patients face. Oleksiw highlighted GLP-1 medications as a prime example, where stigma, dose escalation, and recurring emotional hurdles make specialty therapy adherence especially difficult to sustain.
April 2, 2026
In part two of his Pharmaceutical Commerce interview series, Pleio CEO Michael Oleksiw reframes pharma’s adherence problem as fundamentally human — not logistical. From the industry’s persistent “one-and-done” challenge to the underestimated role of loneliness in early discontinuation, Oleksiw makes the case that lasting behavior change requires meeting patients emotionally before overwhelming them with tools, reminders, or information they aren’t yet ready to act on.